Fig. 4.

The effects of curcumin-loaded immunolipoplex on tumor growth in vivo. a The inhibition of curcumin/LPPC/Herceptin on tumor growth. NOD-SCID mice bearing SKBR-3 tumors (the average tumor size was 55 mm³ for each group) were treated on day 6 with either Cur/LPPC/Rituximab (40 mg/kg curcumin and 4 mg/kg Rituximab), Cur/LPPC/Herceptin (40 mg/kg curcumin and 4 mg/kg Herceptin), Cur + LPPC + Herceptin (40 mg/kg curcumin and 4 mg/kg Herceptin), Cur-H/LPPC/Herceptin (200 mg/kg curcumin and 4 mg/kg Herceptin), or 9 mg/kg Herceptin (clinical dose of Herceptin) via i.v. injection once every 3 ays. The tumor volumes were measured every 2 days after treatment. All values represent the mean ± SD (n = 8). b The tumor sizes observed in the mice in the curcumin/LPPC/Herceptin treatment group on day 6 and day 20 are shown. Each color represents an individual treated mouse, and the line indicates the average tumor size (n = 12). c Mouse survival was monitored daily. The mice were sacrificed when the tumors reached over 2500 mm³ in size